GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Beneish M-Score

Agenus (FRA:AJ8) Beneish M-Score : -0.83 (As of Dec. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.83 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Agenus's Beneish M-Score or its related term are showing as below:

FRA:AJ8' s Beneish M-Score Range Over the Past 10 Years
Min: -5.79   Med: -2.02   Max: 185.3
Current: -0.83

During the past 13 years, the highest Beneish M-Score of Agenus was 185.30. The lowest was -5.79. And the median was -2.02.


Agenus Beneish M-Score Historical Data

The historical data trend for Agenus's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Beneish M-Score Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.47 -5.05 -2.55 -0.80 2.70

Agenus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.87 2.70 -2.02 -1.22 -0.83

Competitive Comparison of Agenus's Beneish M-Score

For the Biotechnology subindustry, Agenus's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Agenus's Beneish M-Score falls into.



Agenus Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Agenus for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1242+0.528 * 7.258+0.404 * 1.2325+0.892 * 1.5594+0.115 * 0.6169
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.549+4.679 * -0.279757-0.327 * 1.6712
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was €0.2 Mil.
Revenue was 22.626 + 21.84 + 25.765 + 76.846 = €147.1 Mil.
Gross Profit was -14.499 + -12.427 + -14.745 + 15.422 = €-26.2 Mil.
Total Current Assets was €45.2 Mil.
Total Assets was €214.9 Mil.
Property, Plant and Equipment(Net PPE) was €137.9 Mil.
Depreciation, Depletion and Amortization(DDA) was €14.0 Mil.
Selling, General, & Admin. Expense(SGA) was €66.1 Mil.
Total Current Liabilities was €243.9 Mil.
Long-Term Debt & Capital Lease Obligation was €49.7 Mil.
Net Income was -59.814 + -49.312 + -56.935 + -42.448 = €-208.5 Mil.
Non Operating Income was 1.696 + 6.634 + -1.018 + -0.039 = €7.3 Mil.
Cash Flow from Operations was -48.016 + -35.469 + -35.136 + -37.049 = €-155.7 Mil.
Total Receivables was €1.0 Mil.
Revenue was 22.782 + 23.348 + 21.39 + 26.796 = €94.3 Mil.
Gross Profit was -25.704 + -31.606 + -34.1 + -30.761 = €-122.2 Mil.
Total Current Assets was €117.6 Mil.
Total Assets was €314.3 Mil.
Property, Plant and Equipment(Net PPE) was €159.0 Mil.
Depreciation, Depletion and Amortization(DDA) was €9.6 Mil.
Selling, General, & Admin. Expense(SGA) was €77.2 Mil.
Total Current Liabilities was €185.9 Mil.
Long-Term Debt & Capital Lease Obligation was €71.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.187 / 147.077) / (0.965 / 94.316)
=0.001271 / 0.010232
=0.1242

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-122.171 / 94.316) / (-26.249 / 147.077)
=-1.295337 / -0.178471
=7.258

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (45.189 + 137.929) / 214.872) / (1 - (117.64 + 159.006) / 314.337)
=0.147781 / 0.119906
=1.2325

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=147.077 / 94.316
=1.5594

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.592 / (9.592 + 159.006)) / (14.012 / (14.012 + 137.929))
=0.056893 / 0.09222
=0.6169

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(66.113 / 147.077) / (77.228 / 94.316)
=0.449513 / 0.818822
=0.549

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((49.703 + 243.85) / 214.872) / ((71.105 + 185.86) / 314.337)
=1.366176 / 0.817483
=1.6712

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-208.509 - 7.273 - -155.67) / 214.872
=-0.279757

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Agenus has a M-score of -0.88 signals that the company is likely to be a manipulator.


Agenus Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Headlines

No Headlines